STOCK TITAN

Moderna (MRNA) SEC Filings, Mar-May 2026

MRNA NASDAQ

Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.

Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.

Rhea-AI Summary

Moderna, Inc. director Hussain Abbas reported an exercise of restricted stock units (RSUs) and a related share sale. On April 30, 2026, RSUs covering 16,233 shares converted into common stock on a one-for-one basis when they vested in full. On May 1, 2026, Abbas sold 5,682 common shares at an average price of $46.63 per share under a pre-arranged Rule 10b5-1 trading plan to generate cash to cover tax liabilities from the RSU vesting. After these transactions, he directly owned 12,066 Moderna common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
insider
-
Rhea-AI Summary

Moderna, Inc. director Elizabeth G. Nabel acquired common shares through an equity award vesting. On April 30, 2026, 16,233 restricted stock units converted into 16,233 shares of common stock on a one-for-one basis. These RSUs vested in full on that date.

After the conversion, Nabel directly owned 19,317 shares of Moderna common stock. The filing shows an exercise or conversion of a derivative security related to compensation, with no open-market purchase or sale reported in this transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
insider
-
Rhea-AI Summary

Moderna director Nader Francois increased his direct equity stake through RSU vesting, not open-market buying. On April 30, 2026, 12,174 restricted stock units converted into the same number of Moderna common shares on a one-for-one basis at an exercise price of $0.00 per share.

These RSUs vested in full on that date, reflecting compensation rather than a market trade. Following the conversion, Francois directly owns 32,781 shares of Moderna common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
insider
Rhea-AI Summary

Moderna director Elizabeth E. Tallett exercised restricted stock units into common shares. On April 30, 2026, 4,058 restricted stock units converted into 4,058 shares of Moderna common stock at an exercise price of $0.00 per share. Following this transaction, she directly holds 4,761 common shares. The restricted stock unit award vested in full on April 30, 2026, and the filing shows no remaining derivative position tied to this award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
insider
-
Rhea-AI Summary

Moderna reported a sharply wider net loss for Q1 2026 as a major legal settlement overshadowed strong vaccine revenue growth. Total revenue rose to $389 million from $108 million, driven by higher COVID vaccine sales, especially in Europe, and increased stand-ready manufacturing revenue.

Net loss deepened to $1.343 billion, or $(3.40) per share, mainly because cost of sales jumped to $955 million, including about $878 million of royalty and settlement-related expenses tied to resolving global litigation with Arbutus and Genevant. R&D and SG&A both declined year over year as the company tightened spending.

Moderna ended the quarter with $7.456 billion in cash, cash equivalents and investments and a long-term term loan of $600 million. It also signed a $50 million propionic acidemia collaboration with Recordati, continued to receive influenza program funding from Blackstone, and secured European Commission approval for its mCOMBRIAX flu–COVID combination vaccine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
quarterly report
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
other
Rhea-AI Summary

Moderna, Inc. reported first quarter 2026 revenue of $389 million, up from $108 million a year earlier, with $311 million from international markets as COVID vaccine sales rose under long-term government partnerships.

The company posted a GAAP net loss of $1.343 billion, or $(3.40) per share, largely due to a $0.9 billion non-recurring litigation settlement charge recorded in cost of sales. Research and development expenses fell 24% to $649 million and selling, general and administrative expenses decreased 18% to $173 million, reflecting wind-down of large respiratory programs and cost discipline. Cash, cash equivalents and investments totaled $7.5 billion as of March 31, 2026, and Moderna is targeting up to 10% revenue growth for 2026 while projecting year-end cash and investments of $4.5 to $5.0 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
current report
-
Rhea-AI Summary

Moderna Inc ownership filing reports that Vanguard Capital Management beneficially owned 25,933,824 shares of Moderna common stock, representing 6.53% of the class. The filing lists sole voting power on 3,061,366 shares and sole dispositive power over 25,933,824 shares, and states these holdings include securities held for Vanguard funds and managed accounts. The filing is signed by Ashley Grim on 04/30/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
ownership
-
Rhea-AI Summary

Moderna, Inc. Chief Financial Officer James M. Mock reported routine equity compensation activity. On April 2, 2026, 1,453 restricted stock units converted into an equal number of common shares. These units vest over time, with 25% having vested on October 5, 2023 and the remainder in twelve equal quarterly installments.

To cover tax withholding obligations tied to this vesting, 703 common shares were withheld at $50.03 per share, rather than sold in the open market. As a result, Mock’s direct holdings increased on a net basis, leaving him with 57,748 common shares and 2,906 restricted stock units directly owned after the transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
insider
Rhea-AI Summary

The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its beneficial ownership of Moderna Inc common stock as 0 shares (0%). The filing explains an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries, and it was signed on 03/27/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
ownership

FAQ

How many Moderna (MRNA) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Moderna (MRNA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Moderna (MRNA)?

The most recent SEC filing for Moderna (MRNA) was filed on November 16, 2026.